Profile data is unavailable for this security.
About the company
Shanghai Medicilon Inc is a China-based company mainly engaged in pre-clinical comprehensive research and development services of biomedicine. The Company is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The Company's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The Company provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
- Revenue in CNY (TTM)1.17bn
- Net income in CNY-172.33m
- Incorporated2004
- Employees2.60k
- LocationShanghai Medicilon IncNo. 585 Chuanda Road, Pudong New AreaSHANGHAI 201299ChinaCHN
- Phone+86 2 158591500
- Fax+86 2 158596369
- Websitehttps://www.medicilon.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assure Tech Hangzhou Co Ltd | 511.29m | 160.91m | 4.59bn | 791.00 | 28.50 | 0.8853 | -- | 8.97 | 1.27 | 1.27 | 4.02 | 40.75 | 0.0799 | 1.52 | 2.67 | 646,379.60 | 2.51 | 31.83 | 2.94 | 38.97 | 38.56 | 65.82 | 31.47 | 47.86 | 8.26 | -- | 0.0166 | 16.05 | -91.84 | 25.18 | -95.35 | 33.51 | 78.77 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.74bn | 91.30m | 4.68bn | 2.08k | 51.23 | 4.29 | -- | 2.69 | 0.2282 | 0.2282 | 4.34 | 2.73 | 0.7747 | 3.12 | 3.65 | 833,613.60 | 4.29 | 7.07 | 6.42 | 11.88 | 49.06 | 60.22 | 5.53 | 7.86 | 1.36 | 6.12 | 0.4994 | 12.00 | 11.91 | 18.26 | 18.78 | 31.10 | 20.01 | -- |
| Yabao Pharmaceutical Group Co Ltd | 2.94bn | 211.62m | 4.72bn | 4.37k | 23.87 | 1.66 | -- | 1.60 | 0.2748 | 0.2748 | 3.82 | 3.95 | 0.7306 | 3.10 | 6.61 | 674,351.30 | 5.20 | 3.22 | 6.79 | 4.70 | 55.22 | 59.72 | 7.12 | 4.93 | 1.68 | 15.30 | 0.0884 | 66.95 | -1.66 | 1.22 | -44.06 | -12.17 | -8.93 | -12.94 |
| Beijing Konruns Pharmaceutical Co Ltd | 998.77m | 146.45m | 4.73bn | 449.00 | 31.61 | 1.48 | -- | 4.74 | 0.9359 | 0.9359 | 6.38 | 20.02 | 0.2803 | 2.95 | 3.93 | 2,224,437.00 | 4.83 | 6.36 | 5.55 | 7.27 | 87.98 | 91.27 | 17.24 | 21.97 | 4.89 | 15.47 | 0.0397 | 22.35 | 7.03 | 7.97 | -31.42 | -26.68 | 23.35 | -- |
| Shanghai Medicilon Inc | 1.17bn | -172.33m | 4.76bn | 2.60k | -- | 1.93 | -- | 4.06 | -1.24 | -1.24 | 9.11 | 18.34 | 0.4205 | 6.63 | 1.64 | 451,437.20 | -6.17 | 9.34 | -7.97 | 11.73 | 12.48 | 36.71 | -14.68 | 14.93 | 2.63 | -- | 0.1229 | 20.18 | -17.68 | 33.26 | -109.82 | -- | 23.60 | -- |
| Getein Biotech Inc | 1.31bn | 244.26m | 4.76bn | 2.14k | 19.50 | 1.80 | -- | 3.65 | 0.4816 | 0.4816 | 2.58 | 5.22 | 0.3502 | 1.61 | 2.77 | 611,337.70 | 6.63 | 13.25 | 9.24 | 18.45 | 66.13 | 65.57 | 18.92 | 28.13 | 1.97 | -- | 0.1857 | 29.88 | -24.85 | 14.81 | -43.92 | 2.31 | 18.44 | 6.00 |
| Innovita Biological Technology Co Ltd | 625.12m | 266.22m | 4.94bn | 404.00 | 18.57 | 2.48 | -- | 7.91 | 1.96 | 1.96 | 4.59 | 14.62 | 0.3093 | 1.67 | 6.23 | 1,547,324.00 | 13.17 | -- | 14.20 | -- | 80.99 | -- | 42.59 | -- | 10.66 | -- | 0.0015 | -- | 7.03 | -- | 15.44 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 2.98m | 2.71% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2023 | 2.47m | 2.24% |
| Harvest Fund Management Co., Ltd.as of 30 Sep 2023 | 1.95m | 1.78% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2023 | 1.68m | 1.53% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Sep 2023 | 1.47m | 1.34% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2023 | 1.26m | 1.14% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 474.38k | 0.43% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2023 | 464.52k | 0.42% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 376.71k | 0.34% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 369.33k | 0.34% |
